Drugs acting on mitochondrial pathways

Akila Srinivasan1*, Sandhiya Selvarajan2, Steven Aibor Dkhar2, Vikneswaran Gunaseelan2

1Department of Pharmacology, 2Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

Received: 11 August 2017
Revised: 01 September 2017
Accepted: 04 September 2017

*Correspondence to:
Dr. Akila Srinivasan,
Email: akilasrinivas@gmail.com

ABSTRACT
Mitochondrion, “the power house” of the cell plays a vital role in generating energy for the intricate functions of the cells. Mitochondria also play important roles in various apoptotic pathways. Around 80-90% of the ATP generated in cells is contributed by these organelles through the process of oxidative phosphorylation. Though this process is essential for the functioning of cells it also generates various Reactive Oxygen Species (ROS), which are toxic to cells. Hence mitochondrial dysfunction is hypothesized to be an important factor in the occurrence of disorders related to aging such as neurodegeneration and malignancies. Several commonly used drugs in clinical practice exert their action by interacting with mitochondrial pathways. This review attempts to focus on the various groups of drugs which act on mitochondria and are utilized for therapy of conditions like cancer, diabetes mellitus, neurodegeneration and so on.

Keywords: Apoptosis, Energy production, Mitochondria, Malignancies, Neurodegeneration, Reactive oxygen species

INTRODUCTION
Mitochondria the power house of various processes generating energy in the cell, are also associated with apoptosis and cardioprotection.1 Around 80-90% of ATP in the cell is produced by mitochondria through oxidative phosphorylation.1

Since oxidative phosphorylation generates reactive oxygen species which are toxic to various cells, it has been hypothesized that mitochondrial dysfunction is a key factor in occurrence of several age related disorders and malignancies.2

DRUGS ACTING ON MITOCHONDRIA
Drugs acting on mitochondria have been utilized in several fields of medicine (Table 1). This review will focus on some drugs which protect mitochondrial function and those drugs which cause mitochondrial toxicity. Newer molecules in the pipeline which interact with mitochondria have also been included.

Targeting mitochondria in malignancies
Cancer cells are actively involved in glycolysis and mitochondrial metabolism which are essential for producing substrates (amino acids, lipids glucose) as well as ATP for cellular proliferation.3 Mitochondrial
metabolism is also stimulated by oncogenic activation to produce ATP and intermediates of TCA cycle which are required for macromolecule synthesis. Some chemotherapeutic agents which act on mitochondria have been described below.

**Paclitaxel**

In a study done on neuroblastoma cell lines, paclitaxel has been found to act through mitochondria and was shown to produce an increase in reactive oxygen species and stimulate the permeability transition pore (PTP) dependent release of cytochrome c which is an apoptogenic factor, in a caspase independent manner.

By opening the mitochondrial PTP, there is a reduction in mitochondrial membrane potential and Ca\(^{2+}\) release from mitochondria, leading to calcium loss, which indicates that some of the acute adverse effects of anti cancer drugs could be due to their effect on mitochondrial function.

**Etoposide**

The cytotoxic property of etoposide (VP-16) induced cell death has been put forward to induction of apoptosis. Several mechanisms have been suggested to identify the signaling pathway for apoptosis.

One such theory is induction of mitochondrial permeability transition (MPT) leading to Ca\(^{2+}\) dependent swelling of the mitochondria and depolarization of mitochondrial membrane potential which is prevented by cyclosporine A, a potent inhibitor of MPT. Other proposed apoptotic mechanisms are activation of caspases, release of cytochrome c and decrease in mitochondrial membrane potential.

**Vinorelbine**

Vinorelbine, a semi-synthetic vinca alkaloid, recruits the pro-apoptotic protein BIM to the mitochondria, where it suppresses the anti apoptotic protein BCL2, thereby making cells treated with this drug undergo apoptosis during interphase.

**Targeting mitochondria in Neurodegenerative disorders**

Various proteins associated with mitochondria such as PTEN-induced putative kinase 1 (PINK1), DJ-1, α-synuclein, leucine-rich repeat kinase 2 and Parkin are implicated in familial Parkinson’s Disease.

The association of mitochondria with idiopathic Parkinson’s disease was first discovered when a postmortem brain of a PD patient showed a complex-I deficiency in the substantia nigra.

These facts have led to the development of newer treatment options for PD directed at mitochondrial metabolism, one of which is MAO inhibitors. MAO is a fundamental enzyme located in mitochondrial outer membrane, which has two isoforms MAO-A (predominant isoform in non neuronal tissue) and MAO-B (major brain isoform). Both selegiline and rasagiline have been shown to be neuroprotective in many studies. But the efficacy of selegiline in treatment of PD has been offset by the neurotoxic metabolites of this drug and to overcome this disadvantage, another drug with a similar mechanism, rasagiline was discovered. The neuroprotective and anti apoptotic actions of rasagiline is brought about by stimulation of anti apoptotic proteins. As a consequence, the drug binds to the binding site in Flavine Adenine Dinucleotide (FAD) in GAPDH and other similar anti apoptotic proteins.

Dysfunction in mitochondrial metabolism has also been linked to Alzheimer’s disease. A reduction in cytochrome oxidase (complex IV) activity in the mitochondria could result in decreased energy stores, leading to the neurodegenerative process. There are various mitochondrial genes which predispose to dementia. In a study done to assess the role of some commonly found mitochondrial DNA haplogroups on dementia risk, it was seen that people who had haplogroup T had a statistically significant risk of developing dementia and haplogroup J exhibited a statistically significant 8 year reduction in Modified Mini-Mental State Examination (3MS) when both were assessed with regard to the common haplogroup H.

Leber’s hereditary optic neuropathy (LHON) is an inherited disorder due to mitochondrial DNA mutations presenting with progressive visual loss due to optic atrophy. Idebenone, an analogue of co enzyme Q10, has been investigated for its role in the therapy of LHON and Friedrich’s ataxia. The first randomized controlled trial performed on idebenone in LHON showed that the drug is safe, well tolerated and benefited people with discordant visual acuities in both eyes, though statistical significance was not attained in the primary end point. This drug has been given authorization for marketing by the European Commission for treatment of LHON in 2015.

**ROLE OF MITOCHONDRIA IN CARDIO PROTECTION**

Ranolazine an anti anginal drug exhibits a protective action on mitochondrial complex I during ischemic reperfusion injury to the heart and decreases damage to complex I indirectly through cytosolic mechanisms which result in improved structural integrity of complex I and reduced its oxidative stress. Similarly the anti hypertensive drug minoxidil exerts its cardioprotective action by activating the ATP sensitive potassium channels situated in the inner membrane of mitochondria (mitoKATP channel) and also reduced the increased mitochondrial Ca\(^{2+}\) concentration induced in myocytes by treatment with ouabain.

International Journal of Basic & Clinical Pharmacology | October 2017 | Vol 6 | Issue 10 | Page 2297
Role in treatment of parasitic infestations

Atovaquone, an antimalarial drug, also possesses action upon other eukaryotic parasitic organisms such as *Pneumocystis carinii* by blocking the electron transport chain. In addition to the above mechanism, atovaquone produced a collapse of the mitochondrial membrane potential, thereby interfering with respiration of malarial parasite within minutes. Ascofuranone, which is an antibiotic derived from a fungus *Ascochyta visiae*, inhibited *Trypanosoma brucei* by inhibiting the function of the electron transport system of the mitochondria and along with glycerol, produced total suppression of the energy production, thereby inhibiting in vitro growth of *Trypanosoma brucei.*

### Diabetes Metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD)

Thiazolidinediones (TZD), which have insulin sensitizing action, have been recently identified to act on two mitochondrial proteins Mpc2 and Mpc1, which are mitochondrial pyruvate carrier complexes. This complex is responsible for regulation of pyruvate entry into the mitochondria and may be a valid target for insulin sensitization.

A study was done in a mouse model to see the effect of acetyl L carnitine and lipoic acid in non alcoholic fatty liver disease. Treatment with this combination was found to improve hepatic mitochondrial content and size along with improvement of carbamoyl phosphate synthase 1, which is a mitochondrial marker.

### Table 1: Various drugs acting on mitochondria.

| Diseases                                      | Drugs (article reference number quoted in brackets) | Site of action in mitochondria                                                                 |
|-----------------------------------------------|-----------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Cancer                                        | Paclitaxel5,6                                       | Stimulates PTP dependent release of cytochrome c (caspase independent)                        |
|                                               | Etoposide7,11                                       | Induction of MPT leading to Ca\(^{2+}\) dependent swelling of the mitochondria               |
|                                               | Vinorelbine12                                       | Depolarization of mitochondrial membrane potential                                            |
|                                               | Selegiline and rasagline15,16                       | Neuroprotection- stimulation of anti apoptotic proteins                                      |
|                                               | Idebenone19,24                                      | Analogue of co enzyme Q10                                                                   |
|                                               | Ranolazine23                                        | Protects and decreases damage to mitochondrial complex I                                     |
|                                               | Minoxidil26                                         | Activates ATP sensitive potassium channels in inner membrane of mitochondria (mitoKATP channel) |
| Malaria, Pneumocystis carinii                 | Atovaquone27,28                                     | Blocks electron transport chain                                                              |
|                                               | Ascofuranone29                                      | Collapses mitochondrial membrane potential                                                  |
| Anti parasitic                               | Thiazolidinediones30                                 | Acts on mitochondrial proteins Mpc2 and Mpc1- target for insulin sensitization               |
| (Trypanosoma brucei)                         |                                                     |                                                                                              |
| Diabetes and metabolic syndrome              |                                                     |                                                                                              |
| NAFLD (Non alcoholic fatty liver disease)    | Acetyl L- carnitine and lipoic acid13                | improves hepatic mitochondrial content and size with improvement of carbamoyl phosphate synthase 1 (a mitochondrial marker) |

PTP: permeability transition pore; MPT: mitochondrial permeability transition; Mpc- mitochondrial pyruvate carrier

Drugs protecting mitochondrial functions

**Resveratrol**

Resveratrol, a polyphenol occurring naturally in plants like grapevines (*Vitis vinifera*), cranberries (*Vaccinium macrocarpon*) and peanuts (*Arachis hypogaea*), has many properties such as anti-cancer property, anti-diabetic property, cardioprotection and neuroprotection. The postulate put forth by mitochondrial theory of aging is that oxidative stress in mitochondria and the production of free radicals that follows this process is the underlying mechanism of aging.

One of the processes by which resveratrol protects mitochondria is by activation of mitochondrial anti oxidant
Elevated levels of Reactive Oxygen Species (ROS) in mitochondria will result in inhibiting the function of important enzymes such as α-ketoglutarate dehydrogenase and aconitase which play a role in mitochondrial metabolism, and may therefore lead to reduced ATP production.\textsuperscript{35}

The cytoprotective effect of resveratrol is due to activation of a transcription factor called Nuclear factor-E2-related factor-2 (Nrf2).\textsuperscript{36} In rodent models of diabetes and aging, activation of the above mentioned Nrf2 dependent pathway helps in promoting cardiovascular and cognitive functioning.\textsuperscript{35}

**Vitamin E**

Well known for its antioxidant property, Vitamin E in high doses was found to restore reduction in mitochondrial respiration and mtNOS (mitochondrial nitric oxide synthase) and complex I and IV activities in rats.\textsuperscript{37} Vitamin E was shown to slow down degenerative processes in tissues by reducing production of hydrogen peroxide in mitochondria of rats and its deficiency can lead to ROS overproduction in mitochondria causing tissue damage.\textsuperscript{38}

**DRUGS CAUSING MITOCHONDRIAL DAMAGE**

**Nucleoside Reverse Transcriptase Inhibitors (NRTI)**

The earliest NRTI 3'-azido-3'-deoxythymidine was shown to inhibit polymerase gamma, which is the enzyme involved in mitochondrial DNA replication in in vitro studies.\textsuperscript{39,40} Clinically this mechanism is responsible for the adverse events in patients receiving NRTI therapy.\textsuperscript{41} These adverse events comprise a wide spectrum from asymptomatic hyperlactatemia (if compensatory mechanisms are effective) to lactic acidosis, which may be fatal.\textsuperscript{41}

**Statins**

Coenzyme Q10 is a principal factor in mitochondrial respiration and its deficiencies can lead to several neurologic syndromes and myopathies.\textsuperscript{42} The synthesis of this compound requires mevalonate, the formation of which is inhibited by statins.\textsuperscript{43} Coenzyme Q10 deficiency produced by statins is one of the actions by which these drugs produce myopathy.\textsuperscript{43} In addition to coenzyme Q deficiency, inhibition of mevalonate pathway by statins can also cause insufficient production of heme A, which is a member of electron transport chain situated in the inner mitochondrial membrane.\textsuperscript{43}

**Non Steroidal Anti Inflammatory Drugs (NSAIDS)**

One of the mechanisms of diclofenac induced hepatotoxicity is triggering of mitochondrial permeability transition (MPT).\textsuperscript{44} When there is opening of MPT pore protons enter the mitochondrial matrix from the intermembrane space, the mitochondrial membrane potential (ΔΨ\textsubscript{m}) is altered unfavourably preventing ATP formation.\textsuperscript{45}

The NSAID nimesulide, which is a weak acid uncoupled mitochondria respiration and causes ATP depletion in human hepatoma cells, which was prevented by albumin.\textsuperscript{46}

**Drugs withdrawn due to mitochondrial toxicity**

Mitochondrial toxicity has played an important role in withdrawal of several drugs from the market. A few of those drugs have been discussed below (Table 2).

**Fialuridine**

In a clinical trial with the drug fialuridine investigated for Hepatitis B infection, seven patients developed hepatic failure, lactic acidosis and pancreatitis, out of which five died.\textsuperscript{47} Surprisingly animal studies did not reveal any such adverse effects.\textsuperscript{37} These multisystemic adverse effects pointed towards severe mitochondrial damage as one of the causes.\textsuperscript{47}

**Troglitazone**

Troglitazone, an anti diabetic drug, was the first thiazolidinedione licensed for use in type 2 diabetes in the United States in the year 1997, but later withdrawn from market because of liver injury associated with its use.\textsuperscript{38} The mechanism of hepatotoxicity could be ascribed to mitochondrial DNA damage caused by this drug.\textsuperscript{49}

**Perhexiline**

In a study done to see the action of the anti anginal drug perhexilene on mitochondria of rats and mice, it was found that this drug uncouples oxidative phosphorylation and reduces beta oxidation of fatty acids. This effect may lead to development of steatosis and pseudoalcoholic liver lesions in humans.\textsuperscript{30} This drug was withdrawn from the global market in 1988.\textsuperscript{51} However the latest techniques of therapeutic drug monitoring for poor metabolisers of CYP2D6 have paved the way for reintroduction of this drug into the market.\textsuperscript{52}

**Tacrine**

The acetylcholinesterase inhibitor Tacrine, developed for treatment in Alzheimers disease has an adverse effect of hepatotoxicity and has been discontinued for use in the United states because of safety issues.\textsuperscript{53} This drug interferes with mitochondrial function by affecting normal activity of complex I and mitochondrial bioenergetics.\textsuperscript{54}

**Newer compounds in the pipeline**

Some novel compounds with action on mitochondria have been discovered and are in clinical trials. Some of them are discussed below.
**Table 2: Drugs withdrawn due to mitochondrial toxicity.**

| Drug          | Adverse event caused                                      |
|---------------|-----------------------------------------------------------|
| Fialuridine47 | hepatic failure, lactic acidosis and pancreatitis         |
| Troglitazone48,49 | Hepatotoxicity- mitochondrial DNA damage                  |
| Perhexiline50,52 | Steatosis and pseudoalcoholic liver lesions               |
| Tacrine53,54 | Hepatotoxicity                                            |

**Olesoxine**

It is a novel neuroprotective compound in the family of cholesterol-oximes which inhibits opening of mitochondrial transition pore by various factors, one of which is oxidative stress.55 It has the property of enhancing the survival of primary rat motor neurons which are deprived of neurotransfactors and is being evaluated for its role in the therapy of Amyotrophic lateral sclerosis (ALS) and Spinal muscular Atrophy (SMA).55

**Lonidamine**

Initially developed as a non hormonal male contraceptive drug, it interferes with energy metabolism by its property of inhibition of hexokinase needed for glycolysis and used this property as a treatment for Benign Prostatic Hyperplasia as the prostate relies on glycolysis for energy production.56 Later this drug was found to possess anti cancer property by interfering with glycolysis and mitochondrial respiration in tumor cells as well as suppressed the activity of mitochondrial pyruvate carrier (MPC), thereby affecting pyruvate uptake in the mitochondria.57

**Betulinic Acid**

A naturally occurring triterpenoid, betulinic acid possesses a wide range of biological properties such as antiretroviral, antimalarial, anti-inflammatory and anti-cancer properties.58 The cytotoxic action of this drug is due to stimulation of mitochondrial apoptotic pathway in tumor cells.59 The fact that normal cells possess considerable resistance to its cytotoxic actions makes this drug a promising agent for treatment of cancers.59

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval: Not required**

**REFERENCES**

1. Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev. 2002;54:101-27.
2. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 2005;39:359-407.
3. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297-308.
4. Dang CV. Links between metabolism and cancer. Genes Dev. 2012;26:877-90.
5. André N, Carré M, Brasseur G, Pourroy B, Kovacic H, Briand C, et al. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett. 2002;532:256-60.
6. Kidd JF, Pilkington MF, Schell MJ, Fogarty KE, Skepper JN, Taylor CW, et al. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem. 2002;277:6504-10.
7. Lindsay GS, Wallace HM. Changes in polynucleotide catabolism in HL-60 human promyelogenous leukaemic cells in response to etoposide-induced apoptosis. Biochem J. 1999;337:83-7.
8. Ferraro C, Quemeneur L, Fournel S, Prigent AF, Revilard JP, Bonnefoy-Berard N. The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes. Cell Death Differ. 2000;7:197-206.
9. Custódio JB, Cardoso CM, Madeira VM, Almeida LM. Mitochondrial permeability transition induced by the anticancer drug etoposide. Toxicol In Vitro. 2001;15:265-70.
10. Meng XW, Fraser MJ, Feller JM, Ziegler JB. Caspase-3-dependent and caspase-3-independent pathways leading to chromatin DNA fragmentation in HL-60 cells. Apoptosis. 2000;5:61-7.
11. Zhuang J, Dinsdale D, Cohen GM. Apoptosis, in human monocyteic THP. 1 cells, results in the release of cytochrome c from mitochondria prior to their ultracondensation, formation of outer membrane discontinuities and reduction in inner membrane potential. Cell Death Differ. 1998;5:953-62.
12. Klotz DM, Nelson SA, Kroboth K, Newton IP, Radulescu S, Ridgway RA, et al. The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively. J Cell Sci. 2012;125:887-95.
13. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008;7:97-109.
14. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden,CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1989;1:1269.
15. Arduino DM, Esteves AR, Oliveira CR, Cardoso SM. Mitochondrial metabolism modulation: a new therapeutic approach for Parkinson's disease. CNS Neurol Disord Drug Targets. 2010;9:105-19.
16. Tabakman R, Lecht S, Lazarovici P. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays. 2004;26:80-90.
17. Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem. 1994;63:2179-84.
18. Tranah GI, Nalls MA, Katzman SM, Yokoyama JS, Lam ET, Zhao Y, et al. Mitochondrial DNA sequence variation associated with dementia and cognitive function in the elderly. J Alzheimer's Dis. 2012;32:357-72.
19. Fraser JA, Biousse V, Newman NJ. The neuroophthalmology of mitochondrial disease. Surv Ophthalmol. 2010;55:299-334.
20. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies—disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011;30:81-114.
21. Yu-Wai-Man P, Votruba M, Moore AT, Chinnery PF. Treatment strategies for inherited optic neuropathies: past, present and future. Eye (Lond). 2014;28:521-37.
22. Klopkov T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Baille M, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain. 2011;134:2677-86.
23. Drugs.com. Raxone. Available at: https://www.drugs.com/uk/raxone.html. Accessed 19 May 2017.
24. Radke J. Drug (Raxone) wins approval in Europe to treat rare blind condition. Rare Disease Report. September 9, 2015. Available at: http://www.raredrn.com/news/raxone-approval-europe-lhln. Accessed May 9 2017.
25. Gadicherla AK, Stowe DF, Antholine WE, Yang M, Camara AK. Damage to mitochondrial complex I during cardiac ischemia reperfusion injury is reduced indirectly by anti-anginal drug ranolazine. Biochim Biophys Acta. 2012;1817:419-29.
26. Sato T, Li Y, Saito T, Nakaya H. Minoxidil opens mitochondrial KATP channels and confers cardioprotection. Br J Pharmacol. 2004;141:360-6.
27. Hughes WT, Gray VL, Gutteridge WE, Latter VS, Pudney M. Efficacy of a hydroxyxanthequinoine, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1990;34:225-8.
28. Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem.1997;272:3961-6.
29. Minagawa N, Yabu Y, Kita K, Nagai K, Ohta N, Meguro K, et al. An antibiotic, ascorufanone, specifically inhibits respiration and in vitro growth of long slender bloodstream forms of Trypanosoma brucei brucei. Mol Biochem Parasitol. 1997;84:271-80.
30. Colca JR, McDonald WG, Cavey GS, Cole SL, Holewa DD, Brightwell-Conrad AS, et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PloS One. 2013;8:e61551.
31. Kathirvel E, Morgan K, French SW, Morgan TR. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease. Nutr Res.2013;33:932-41.
32. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493-506.
33. Van Remmen H, Jones DP. Current thoughts on the role of mitochondria and free radicals in the biology of aging. J Gerontol A Biol Sci Med Sci. 2009;64:171-4.
34. Ungvari Z, Labinskyy N, Mukhopadhyay P, Pinto JT, Bagi Z, Ballabh P, et al. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol. 2009;297:H1876-81.
35. Ungvari Z, Sonntag WE, De Cabo R, Baur JA, Csiszar A. Mitochondrial protection by resveratrol. Exerc Sport Sci Rev. 2011;39:128-32.
36. Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol. 2010;299:H18-24.
37. Navarro A, Bandez MJ, Lopez-Cepero JM, Gómez C, Boveris A. High doses of vitamin E improve mitochondrial dysfunction in rat hippocampus and frontal cortex upon aging. Am J Physiol Regul, Integr Comp Physiol. 2011;300:R827-34.
38. Chow CK, Ibrahim W, Wei Z, Chan AC. Vitamin E regulates mitochondrial hydrogen peroxide generation. Free Radic Biol Med. 1999;27:580-7.
39. Simpson MV, Chin CD, Keilbaugh SA, Lin TS, Prussoff WH. Studies on the inhibition of mitochondrial DNA replication by 3’-azido- 3’-deoxythymidine and other deoxyoxynucleoside analogs which inhibit HIV-1 replication, Biochem Pharmacol. 1989;38:1033-6.
40. Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2’,3’-dideoxyctydine. J Biol Chem. 1989;264:11934-7.
41. Pinti M, Salomoni P, Cossarizza A. Anti-HIV drugs and the mitochondria. Biochim Biophys Acta. 2006;1757:700-7.
42. Deichmann R, Lavin C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. Ochsner J. 2010;10:16-21.
43. Manoukian AA, Bhagavan NV, Hayashi T, Nestor TA, Rios C, Scottoni AG. Rhabdomyolysis secondary to lovastatin therapy. Clin Chem. 1990;36:2145-7.
44. Masubuchi Y, Nakayama S, and Horie T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology. 2002;35:544-51.
45. Pessayre D, Mansouri B, Fromenty B, and Berson A. Hepatotoxicity due to mitochondrial injury, in Drug-
Induced Liver Disease (editors: Kaplowitz N and DeLeve L), Marcel Dekker, New York; 2002;55-84.

46. Berson A, Cazanova S, Descatoire V, Tinel M, Grodet A, Wolf C, et al. The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxymethane-sulfoamidine), uncouples mitochondria and induces mitochondrial permeability transition in human hepatoma cells: protection by albumin. J Pharmacol Exp Ther. 2006;318:444-54.

47. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333:1099-105.

48. United States National Library of Medicine. National Institute of Diabetes and Digestive and Kidney diseases. Liver Tox. Available at: https://livertox.nih.gov/Troglitazone.htm. Accessed 4 May 2017.

49. Rachek LI, Yuzefovych LV, LeDoux SP, Julie NL, Wilson GL. Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol Appl Pharmacol. 2009;240:348-54.

50. Deschamps D, DeBeco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D. Inhibition by perhexiline of oxidative phosphorylation and the β-oxidation of fatty acids: Possible role in pseudoalcoholic liver lesions. Hepatology. 1994;19:948-61.

51. Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market?. Pharmacogenomics. 2006;7:889-908.

52. Ashrafian H, Horowitz ID, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev. 2007;25:76-97.

53. United States Food and Drug Administration. Orange book. Tacrine hydrochloride- discontinued. Available at: https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm. Accessed 19 May 2017.

54. Melo T, Videira RA, Andre S, Maciel E, Francisco CS, Oliveira-Campos AM, et al. Tacrine and its analogues impair mitochondrial function and bioenergetics: A lipidomic analysis in rat brain. J Neurochem. 2012;120:998-1013.

55. Bordet T, Berna P, Abitbol JL, Pruss RM. Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals. 2010;3:345-68.

56. Roehrborn CG. The development of lonidamine for benign prostatic hyperplasia and other indications. Rev Urol. 2005;7:S12-20.

57. Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, et al. Mechanism of antineoplastic activity of lonidamine. Biochim Biophys Acta. 2016;1866:151-62.

58. Yogeeswari P, Sriman D. Betulinic acid and its derivatives: a review on their biological properties. Curr Med Chem. 2005;12:657-66.

59. Fulda S. Betulinic acid for cancer treatment and prevention. Int J Mol Sci. 2008;9:1096-107.

Cite this article as: Srinivasan A, Selvarajan S, Dhar SA, Gunaseelan V, Drugs acting on mitochondrial pathways. Int J Basic Clin Pharmacol 2017;6:2296-302.